Ida Robertsen
Overview
Explore the profile of Ida Robertsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vethe N, Asberg A, Bergan S, Robertsen I, Midtvedt K
Ther Drug Monit
. 2024 Nov;
47(1):98-104.
PMID: 39560611
Background: Home-based hospital services are becoming increasingly popular, and the addition of remote outpatient appointments after kidney transplantation facilitates more practical and closer follow-up. In this context, finger-prick self-sampling is...
2.
Drevland O, Grasdal M, Carlsen R, Midtvedt K, Robertsen I, Jenssen T, et al.
Transplant Direct
. 2024 Nov;
10(12):e1733.
PMID: 39553740
Background: Hyperkalemia is common in kidney transplant (KTx) recipients. Patiromer, a potassium-binding polymer used to treat acute and chronic hyperkalemia, has the potential to bind charged particles in the gastrointestinal...
3.
Karlsson C, Johnson L, Greasley P, Retterstol K, Hedberg J, Hall M, et al.
JAMA Surg
. 2024 Jul;
159(9):971-980.
PMID: 38959017
Importance: Roux-en-Y gastric bypass (RYGB) is associated with reduced cardiovascular (CV) risk factors, morbidity, and mortality. Whether these effects are specifically induced by the surgical procedure or the weight loss...
4.
Kvitne K, Hjelmesaeth J, Hovd M, Sandbu R, Johnson L, Andersson S, et al.
Clin Pharmacol Ther
. 2024 May;
116(3):647-652.
PMID: 38771070
This article summarizes the lessons learned from the COCKTAIL study: an open, three-armed, single-center study including patients with obesity scheduled for treatment with Roux-en-Y gastric bypass (RYGB) or nonsurgical calorie...
5.
Kvitne K, Hovd M, Johnson L, Wegler C, Karlsson C, Artursson P, et al.
Clin Pharmacokinet
. 2023 Nov;
63(1):109-120.
PMID: 37993699
Background And Objective: Several drugs on the market are substrates for P-glycoprotein (P-gp), an efflux transporter highly expressed in barrier tissues such as the intestine. Body weight, weight loss, and...
6.
Kvitne K, Drevland O, Haugli N, Skadberg E, Zare H, Asberg A, et al.
Clin Pharmacokinet
. 2023 May;
62(7):981-987.
PMID: 37162619
Background And Objective: Midazolam is the preferred clinical probe drug for assessing CYP3A activity. We have previously shown substantial intraindividual variability in midazolam absolute bioavailability and clearance in patients with...
7.
Hovd M, Robertsen I, Woillard J, Asberg A
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111559
In combination with Bayesian estimates based on a population pharmacokinetic model, limited sampling strategies (LSS) may reduce the number of samples required for individual pharmacokinetic parameter estimations. Such strategies reduce...
8.
Hovd M, Robertsen I, Johnson L, Krogstad V, Wegler C, Kvitne K, et al.
Clin Pharmacokinet
. 2023 Mar;
62(5):725-735.
PMID: 36988826
Introduction: Rosuvastatin pharmacokinetics is mainly dependent on the activity of hepatic uptake transporter OATP1B1. In this study, we aimed to investigate and disentangle the effect of Roux-en-Y gastric bypass (RYGB)...
9.
Drevland O, Robertsen I, Theie Gustavsen M, Kveim H, Hovd M, Midtvedt K, et al.
Transplant Direct
. 2023 Mar;
9(3):e1448.
PMID: 36875939
Methods: RTRs with stable graft function treated with tacrolimus, prednisolone, and MMF (750 mg BID) were included in this open, nonrandomized study. Two 12-h pharmacokinetic investigations were conducted in succession...
10.
Kvitne K, Hole K, Molden E, Robertsen I
Eur J Clin Pharmacol
. 2022 Sep;
78(11):1865-1866.
PMID: 36098754
No abstract available.